HK1018219A1 - A pharmaceutical composition for the treatment of autoimmune diseases - Google Patents

A pharmaceutical composition for the treatment of autoimmune diseases

Info

Publication number
HK1018219A1
HK1018219A1 HK99103337A HK99103337A HK1018219A1 HK 1018219 A1 HK1018219 A1 HK 1018219A1 HK 99103337 A HK99103337 A HK 99103337A HK 99103337 A HK99103337 A HK 99103337A HK 1018219 A1 HK1018219 A1 HK 1018219A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
pct
treatment
autoimmune diseases
date
Prior art date
Application number
HK99103337A
Other languages
English (en)
Inventor
Angelo Guglielmotti
Paolo Dionisio
Original Assignee
Angelini Ricerche Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11372453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1018219(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angelini Ricerche Spa filed Critical Angelini Ricerche Spa
Publication of HK1018219A1 publication Critical patent/HK1018219A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HK99103337A 1995-10-31 1999-08-03 A pharmaceutical composition for the treatment of autoimmune diseases HK1018219A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95MI002242A IT1276031B1 (it) 1995-10-31 1995-10-31 Composizione farmaceutica per il trattamento delle malattie autoimmuni
PCT/EP1996/004672 WO1997016185A2 (en) 1995-10-31 1996-10-26 A pharmaceutical composition for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
HK1018219A1 true HK1018219A1 (en) 1999-12-17

Family

ID=11372453

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99103337A HK1018219A1 (en) 1995-10-31 1999-08-03 A pharmaceutical composition for the treatment of autoimmune diseases

Country Status (27)

Country Link
US (1) US6020356A (pl)
EP (1) EP0858337B1 (pl)
JP (1) JP4007615B2 (pl)
KR (1) KR19990067237A (pl)
CN (1) CN1229113C (pl)
AT (1) ATE326965T1 (pl)
AU (1) AU721841B2 (pl)
BR (1) BR9611320B1 (pl)
CA (1) CA2236256C (pl)
CZ (1) CZ292258B6 (pl)
DE (1) DE69636167T2 (pl)
DK (1) DK0858337T3 (pl)
EA (1) EA000826B1 (pl)
ES (1) ES2264144T3 (pl)
HK (1) HK1018219A1 (pl)
HU (1) HU228051B1 (pl)
IL (1) IL124291A (pl)
IT (1) IT1276031B1 (pl)
MX (1) MX9803478A (pl)
NO (1) NO324130B1 (pl)
NZ (1) NZ321580A (pl)
PL (1) PL186377B1 (pl)
PT (1) PT858337E (pl)
SK (1) SK284069B6 (pl)
TR (1) TR199800765T2 (pl)
WO (1) WO1997016185A2 (pl)
ZA (1) ZA969060B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
ES2335008T3 (es) * 2003-04-24 2010-03-18 Jagotec Ag Comprimido con nucleo coloreado.
ES2400446T5 (es) 2006-08-03 2017-03-13 Horizon Pharma Ag Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
BR112012002130A2 (pt) 2009-08-03 2015-09-15 Aziende Chimique Riunite Angelini Francesco A C R A F S P A processo para a preparação de composto,e, composto intermediário
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) * 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
AU2013255050B2 (en) * 2012-05-01 2016-07-28 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04506066A (ja) * 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
AU7376494A (en) * 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
EP0827404A1 (en) * 1995-05-10 1998-03-11 Pfizer Inc. Combination of methotrexate and tenidap for the treatment of rheumatoid arthritis

Also Published As

Publication number Publication date
ITMI952242A0 (pl) 1995-10-31
BR9611320B1 (pt) 2010-08-10
US6020356A (en) 2000-02-01
DK0858337T3 (da) 2006-09-18
JP4007615B2 (ja) 2007-11-14
NO981951D0 (no) 1998-04-29
CA2236256C (en) 2005-02-22
EA000826B1 (ru) 2000-04-24
ITMI952242A1 (it) 1997-05-01
EA199800417A1 (ru) 1998-10-29
NO981951L (no) 1998-06-29
PL186377B1 (pl) 2003-12-31
PT858337E (pt) 2006-09-29
WO1997016185A2 (en) 1997-05-09
AU721841B2 (en) 2000-07-13
CZ132698A3 (cs) 1998-10-14
HUP9901303A3 (en) 2001-04-28
DE69636167T2 (de) 2007-03-29
NO324130B1 (no) 2007-09-03
KR19990067237A (ko) 1999-08-16
CZ292258B6 (cs) 2003-08-13
SK284069B6 (sk) 2004-09-08
CN1229113C (zh) 2005-11-30
CN1207042A (zh) 1999-02-03
EP0858337A2 (en) 1998-08-19
ATE326965T1 (de) 2006-06-15
ES2264144T3 (es) 2006-12-16
HUP9901303A2 (hu) 1999-09-28
AU7493896A (en) 1997-05-22
ZA969060B (en) 1997-05-29
JPH11515020A (ja) 1999-12-21
MX9803478A (es) 1998-11-30
PL326371A1 (en) 1998-09-14
CA2236256A1 (en) 1997-05-09
NZ321580A (en) 2000-02-28
WO1997016185A3 (en) 1997-07-03
EP0858337B1 (en) 2006-05-24
SK57998A3 (en) 1998-12-02
DE69636167D1 (de) 2006-06-29
TR199800765T2 (xx) 1998-08-21
IT1276031B1 (it) 1997-10-24
IL124291A (en) 2001-06-14
HU228051B1 (en) 2012-09-28
BR9611320A (pt) 1999-03-02

Similar Documents

Publication Publication Date Title
MY126555A (en) Oral pharmaceutical extended release dosage form
IL122546A0 (en) Use of a combination of ritonavir and a drug metabolized by cytochrome p450 monooxygenase in the preparation of medicaments and pharmaceutical compositions containing the combination
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
NZ514574A (en) Novel method of treatment
NO954996L (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
CA2157879A1 (en) Methods for Inhibiting Bone Loss with 3,4-Diarylchroman
ZA969060B (en) A pharmaceutical composition for the treatment of autoimmune diseases
ATE235901T1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma- butyrobetain für die behandlung von herz-gefäss- erkrankungen
IL143985A0 (en) New use of melagatran
GEP20063719B (en) Prevention of Migraine Recurrence
CA2217513A1 (en) Pharmaceutical agents for the treatment of alzheimer's disease
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
TW285640B (pl)
BG106151A (en) Pharmaceutical complex
AU2392797A (en) Use of benzonaphthalene derivatives for the manufacture of medicaments for the treatment of diseases of the nervous system
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
WO1998038986A3 (en) Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
RU95111888A (ru) Способ лечения периферических поражений лицевого нерва
MX9706825A (es) El uso farmacologico de ciertos derivados de cistina.